{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:38:38Z","timestamp":1784734718556,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1053\/j.semnuclmed.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:34:24Z","timestamp":1741268064000},"page":"221-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Theranostics in Lung Neuroendocrine Tumors"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-4100","authenticated-orcid":false,"given":"Indraja D.","family":"Dev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-992X","authenticated-orcid":false,"given":"Ameya D.","family":"Puranik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos A.","family":"Trikalinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley John","family":"Girod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.010_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1053\/j.semnuclmed.2025.02.010_bib0002","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.3390\/cancers15225440","article-title":"Lung carcinoids: a comprehensive review for clinicians","volume":"15","author":"Granberg","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jtho.2018.10.166","article-title":"Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors","volume":"14","author":"Yoon","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms23031447","article-title":"Role of somatostatin signalling in neuroendocrine tumours","volume":"23","author":"Rogoza","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2967\/jnumed.123.266185","article-title":"Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of DOTATATE PET scans","volume":"64","author":"Al-Toubah","year":"2023","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0007","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers10120510","article-title":"Management of typical and Atypical pulmonary carcinoids based on different established guidelines","volume":"10","author":"Gosain","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0008","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10446","key":"10.1053\/j.semnuclmed.2025.02.010_bib0009","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.02.010_bib0010","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/jcm12113719","article-title":"A systematic review on combined [18F]FDG and 68Ga-SSA PET\/CT in pulmonary carcinoid","volume":"12","author":"Prosperi","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.010_bib0011","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1148\/rg.336135506","article-title":"Spectrum of pulmonary neuroendocrine proliferations and neoplasms","volume":"33","author":"Benson","year":"2013","journal-title":"Radiographics"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0012","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1245\/s10434-012-2617-7","article-title":"Utility of \u00b9\u00b9\u00b9indium-pentetreotide scintigraphy in patients with neuroendocrine tumors","volume":"20","author":"Shaverdian","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.010_bib0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/0100-3984.2021.0038","article-title":"68Ga-DOTATATE PET\/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study","volume":"55","author":"Cavicchioli","year":"2022","journal-title":"Radiol Bras"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.010_bib0014","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.010_bib0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/MNM.0000000000001248","article-title":"Does 68Ga-DOTA-NOC-PET\/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?","volume":"41","author":"Purandare","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.010_bib0016","doi-asserted-by":"crossref","first-page":"e14769","DOI":"10.1097\/MD.0000000000014769","article-title":"The utility of 18F-FDG and 68Ga-DOTA-peptide PET\/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.02.010_bib0017","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: european Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.02.010_bib0018","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0019","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers10120510","article-title":"Management of typical and atypical pulmonary carcinoids based on different established guidelines","volume":"10","author":"Gosain","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2967\/jnumed.123.266185","article-title":"Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of DOTATATE PET scans","volume":"64","author":"Al-Toubah","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.010_bib0021","first-page":"4167","article-title":"The diagnostic and prognostic role of combined [18F]FDG and [68Ga]-DOTA-peptides PET\/CT in primary pulmonary carcinoids: a multicentric experience","volume":"33","author":"Albano","year":"2023","journal-title":"EurRadiol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.02.010_bib0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","article-title":"New PET radiotracers for the imaging of neuroendocrine neoplasms","volume":"23","author":"Fortunati","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0023","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/02841868909111201","article-title":"Chromogranins\u2013new sensitive markers for neuroendocrine tumors","volume":"28","author":"Eriksson","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.beem.2016.01.002","article-title":"Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms","volume":"30","author":"Modlin","year":"2016","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0025","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-11-2893","article-title":"L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer","volume":"18","author":"Hai","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02739970","article-title":"Proliferation markers and their uses in the study of endocrine tumors","volume":"7","author":"Pelosi","year":"1996","journal-title":"Endocr Pathol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00019606-199206000-00006","article-title":"Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications","volume":"1","author":"Roncalli","year":"1992","journal-title":"Diagn Mol Pathol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four world health organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J Pathol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0029","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-015-1989-z","article-title":"Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma","volume":"141","author":"Matsumura","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.lungcan.2020.06.005","article-title":"ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: clinical and molecular description of two cases","volume":"146","author":"Fares","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0031","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"Westcott","year":"2013","journal-title":"Chin J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0032","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fonc.2016.00094","article-title":"Notch signaling in neuroendocrine tumors","volume":"6","author":"Crabtree","year":"2016","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0033","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1210\/jc.2018-01931","article-title":"Somatostatin receptor expression is associated with metastasis and patient outcome in pulmonary carcinoid tumors","volume":"104","author":"Vesterinen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0034","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/lungindia.lungindia_482_19","article-title":"Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience","volume":"38","author":"Pasala","year":"2021","journal-title":"Lung India"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0035","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.3233\/TUB-220044","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","journal-title":"Tumour Biol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0036","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/modpathol.2014.74","article-title":"Different micro-rna expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study","volume":"27","author":"Mairinger","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0037","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11864-013-0246-4","article-title":"Evolving treatment strategies for management of carcinoid tumors","volume":"14","author":"Strosberg","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0038","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5858\/arpa.2013-0119-OA","article-title":"Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors","volume":"138","author":"Naranjo Gomez","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0039","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/ERC-13-0042","article-title":"Mtor, p70S6K, AKT, and ERK1\/2 levels predict sensitivity to mTOR and PI3K\/mTOR inhibitors in human bronchial carcinoids","volume":"20","author":"Gagliano","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0041","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/crj.12603","article-title":"Well-differentiated bronchial neuroendocrine tumors: clinical management and outcomes in 105 patients","volume":"12","author":"Pericleous","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0042","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/pin.12486","article-title":"Glut1: a novel tool reflecting proliferative activity of lung neuroendocrine tumors?","volume":"67","author":"Benzerdjeb","year":"2017","journal-title":"Pathol Int"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.010_bib0043","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.athoracsur.2009.07.097","article-title":"Management of carcinoid tumors","volume":"89","author":"Detterbeck","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.02.010_bib0044","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0003-4975(98)00083-6","article-title":"Operative risk and prognostic factors of typical bronchial carcinoid tumors","volume":"65","author":"Ducrocq","year":"1998","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lungcan.2003.11.016","article-title":"Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy","volume":"44","author":"Wirth","year":"2004","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.010_bib0046","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0047","article-title":"Phase 3 trial of Cabozantinib to treat advanced neuroendocrine tumors","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0048","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers10120510","article-title":"Management of typical and Atypical pulmonary carcinoids based on different established guidelines","volume":"10","author":"Gosain","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"28","key":"10.1053\/j.semnuclmed.2025.02.010_bib0049","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","article-title":"Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids","volume":"75","author":"Sullivan","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.02.010_bib0051","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2016.11.004","article-title":"Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of 18FDG-PET\/CT","volume":"18","author":"Bongiovanni","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.02.010_bib0052","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0337","article-title":"Treatment of advanced BP-NETS with lanreotideautogel\/depot vs placebo: the phase III SPINET study","volume":"31","author":"Baudin","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.010_bib0053","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"RAD001 in advanced neuroendocrine tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"9808","key":"10.1053\/j.semnuclmed.2025.02.010_bib0054","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"10022","key":"10.1053\/j.semnuclmed.2025.02.010_bib0055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.010_bib0056","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtho.2020.06.021","volume":"15","author":"Singh","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0057","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000402936","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"44","author":"Bodei","year":"2015","journal-title":"Front Horm Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0058","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10446","key":"10.1053\/j.semnuclmed.2025.02.010_bib0059","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0060","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2967\/jnumed.120.260760","article-title":"Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study","volume":"63","author":"Zidan","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0061","series-title":"Testing lutetium Lu 177 dotatate in patients with somatostatin receptor positive advanced bronchial neuroendocrine tumors","year":"2025"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.010_bib0062","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.cllc.2019.02.007","article-title":"Peptide receptor radionuclide therapy for patients with advanced lung carcinoids","volume":"20","author":"Naraev","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.010_bib0063","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.010_bib0064","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","article-title":"Long-term results of PRRT in advanced bronchopulmonary carcinoid","volume":"43","author":"Mariniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"25","key":"10.1053\/j.semnuclmed.2025.02.010_bib0065","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"NETTER-1 study group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0066","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/RLU.0000000000001639","article-title":"Clinical response of metastatic\/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"42","author":"Parghane","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.02.010_bib0067","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.02.010_bib0068","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.prp.2012.05.014","article-title":"Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung","volume":"208","author":"Tsuta","year":"2012","journal-title":"Pathol Res Pract"},{"issue":"14","key":"10.1053\/j.semnuclmed.2025.02.010_bib0069","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.3390\/cancers15143595","article-title":"In-vivo somatostatin-receptor expression in small cell lung cancer as a prognostic image biomarker and therapeutic target","volume":"15","author":"\u015een","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.010_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the 177Lu-DOTA0-Tyr3-octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Kim","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0071","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1158\/1535-7163.MCT-23-0029","article-title":"RYZ101 (Ac-225 DOTATATE) Opportunity beyond gastroenteropancreatic neuroendocrine tumors: preclinical efficacy in small-cell lung cancer","volume":"22","author":"Han","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0072","unstructured":"ClinicalTrials.gov, National Library of Medicine (U.S.) (2024), Study of RYZ101 in combination with SoC in subjects with SSTR+ ES-SCLC. Accessed January 18, 2025 from: https:\/\/clinicaltrials.gov\/study\/NCT05595460."},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0073","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000381061","article-title":"Expression of somatostatin receptors 1-5 and dopamine receptor 2 in lung carcinoids: implications for a therapeutic role","volume":"101","author":"Kanakis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0074","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.010_bib0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00259-020-04915-7","article-title":"Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT","volume":"48","author":"Zidan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0076","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000486282","article-title":"Real-world treatment patterns for lung neuroendocrine tumors: a claims database analysis","volume":"94","author":"Broder","year":"2018","journal-title":"Oncology"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0077","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/ph14101005","article-title":"Combination therapies with PRRT","volume":"14","author":"Yordanova","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.010_bib0078","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0079","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3177","article-title":"177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial","volume":"42","author":"Garcia-Alvarez","year":"2024","journal-title":"JCO"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.02.010_bib0080","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.010_bib0081","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241297578","article-title":"Efficacy, safety, and prognostic factors of capecitabine plus temozolomide regimen in patients with atypical thymic carcinoids","volume":"16","author":"Liu","year":"2024","journal-title":"Ther Adv Med Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:41:00Z","timestamp":1741909260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0001299825000170"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.010","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostics in Lung Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}